PSC 432 Chapter 34: Antimycobacterial Drugs
17 Feb 2019
School
Department
Course
Professor
Document Summary
Although treatment regimens vary in duration and in the agents employed, they always. Defined as resistant to any fluoroquinolone and at least 1/3 injectable 2nd-line drugs (capreomycin, kanamycin and amikacin) in addition to mdr-tb. Active against all populations of bacilli: when used alone, resistant organisms rapidly emerge, resistance: associated with different chromosomal mutations, pharmacokinetics: orally administered isoniazid is readily absorbed, adverse effects: fairly low. Evaluated before start and at monthly intervals during treatment. Discontinuation: other adverse effects: mental abnormalities, convulsions in patients prone to seizures, and optic neuritis have been observed, drug interactions: inhibits metabolism of phenytoin and may potentiate the adverse effects of that. Rifampin drug: never given as a single agent in the treatment of active tuberculosis, due to development of resistance, rifampin blocks transcription by interacting with the beta subunit of bacterial dna dependent. Rna polymerase: rifampin is bactericidal for both intracellular and extracellular mycobacteria, including m tuberculosis and atypical mycobacteria, such as m kansasii.
